通过FXR激活提升LCN13的表达改善肝细胞脂质积累和炎症
Xingliang Qin1, Yongyao Tan1, Weishu Ren1
1Key Laboratory of Tropical Disease Control (Sun Yat-sen University), MinisCtry of Education, Guangzhou 510080, China; Research Center for Clinical Laboratory Standard, Department of Immunology and Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
利波卡林13 (LCN13) 能预防与代谢功能障碍相关的脂肪肝炎 (MASH). 较低的LCN13水平会使MASH恶化,而通过FXR激活MASH则为肝脏疾病提供了一种新的治疗策略.
科学领域:
- 肝病学和代谢研究.
- 分子生物学分子生物学
- 脂质代谢 脂质代谢是什么
背景情况:
- 利波卡林13 (LCN13) 具有抗肥胖和抗糖尿病的特性.
- 在代谢功能障碍相关的脂肪性肝病 (MASLD),特别是MASH中,LCN13的作用仍未得到研究.
- MASLD和MASH与肥胖和胰岛素抵抗有关.
研究的目的:
- 研究内源性LCN13在MASH发育中的作用.
- 评估LCN13在MASH和相关代谢功能障碍中的治疗潜力.
- 在MASH的背景下阐明LCN13表达的调节机制.
主要方法:
- 利用缺乏甲胺-胆的饮食和MASH细胞模型来研究LCN13.
- 通过生物化学测定和组织学染色,评估脂质积累和炎症.
- 采用RNA测序,ChIP和光酶试验来确定LCN13的FXR调节.
主要成果:
- 在MASH患者和模型中,LCN13表达减少.
- 在体外,LCN13的过度表达抑制了脂质积累和炎症;降低调节加剧了这些情况.
- 确定FXR是直接调节LCN13的转录因子,FXR激活改善了MASH表型.
结论:
- LCN13在MASH发育中起着保护作用.
- 通过FXR介导的LCN13激活为MASH提供了一个新的治疗途径.
- 这些发现为治疗MASH和相关代谢障碍提供了新的见解.
更多相关视频
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
相关概念视频
Inflammation
Cholesterol: Significance and Regulation
Considering cholesterol and...
Cell Specific Gene Expression
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
